Q&A: Seaport CEO and CSO on learning from Karuna and the future of CNS research

Q&A: Seaport CEO and CSO on learning from Karuna and the future of CNS research

Seaport Therapeutics began trading as a public company on Friday after executives rang the Nasdaq’s opening bell. Shares rose {$SPTX} more than 20%. With a team largely made up of Karuna Therapeutics veterans, Seaport is ...

Original Source

Read the full article at Endpoints →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.